Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2679Pancreatic Neoplasms 1470Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Rectal Neoplasms 980Esophageal Neoplasms 728Neoplasms 559Liver Neoplasms 533Breast Neoplasms 473Neoplasm Metastasis 373Lung Neoplasms 325Carcinoma, Non-Small-Cell Lung 292Gastrointestinal Neoplasms 277Ovarian Neoplasms 258Prostatic Neoplasms 229Cholangiocarcinoma 221Head and Neck Neoplasms 180Gastrointestinal Stromal Tumors 176Melanoma 165Esophageal Squamous Cell Carcinoma 164Barrett Esophagus 156Uterine Cervical Neoplasms 151Biliary Tract Neoplasms 149Adenocarcinoma Of Esophagus 148Gallbladder Neoplasms 136Carcinoma, Renal Cell 134Urinary Bladder Neoplasms 132Sarcoma 131Anus Neoplasms 124

Interventions

pembrolizumab 1paricalcitol 1Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Resectable Pancreatic Carcinoma × Gastrointestinal × Clear all
NCT02930902 2023-02-09

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Resectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡